One of our most distinguished clinicians, Prof Sir Mark Caulfield, has been appointed a non-executive director of Barts Health NHS Trust.
He replaces Prof Steve Thornton as the nominated representative on the Trust Board for our academic partners and neighbours at Queen Mary University of London (QMUL).
Sir Mark is one of the country’s leading authorities on genomic medicine research, and was recently appointed Chief Executive of Barts Life Sciences, our collaboration on cutting-edge clinical innovation with QMUL.
Until recently he was Chief Scientist at Genomics England, where he was instrumental in delivering the 100,000 Genomes Project which has delivered life-changing results for many patients. He was knighted for this work in 2019.
He remains Professor of Clinical Pharmacology in the William Harvey Research Institute at QMUL, in which capacity he has made substantial contributions to the discovery of genes related to cardiovascular health, cancer and rare diseases, with his research changing national and international guidance for high blood pressure.
Sir Mark trained in clinical pharmacology at St Bartholomew’s hospital, was a leading force in the creation of the Barts Heart Centre, directs the NIHR Biomedical Research Centre based at the hospital, and still practices as a consultant in the blood pressure clinic.
Prof Thornton, a consultant obstetrician and vice-president for health at QMUL, stepped down from the Board after being seconded to UCL Partners as interim managing director.